Calder Biosciences
Calder Biosciences is a nano-scale, molecular engineering company applying its platform technology to engineer and develop novel vaccines. They focus on creating safe, effective, durable, and tolerable vaccines against viral infections such as RSV, influenza, and EBV. Their proprietary 3D-Vaxlock™ technology engineers site-specific, covalent crosslinks into proteins to lock them in their most potent 3D shape, enhancing vaccine stability, safety, and efficacy. Calder aims to develop vaccines with global health impact, lower costs, and easier distribution.
Industries
Nr. of Employees
small (1-50)
Calder Biosciences
New York, New York, United States, North America
Products
RSV vaccine candidate (dityrosine‑stabilized prefusion F)
A recombinant prefusion F protein immunogen stabilized by targeted dityrosine crosslinks to retain prefusion conformation, increase thermostability and elicit higher neutralizing antibody titers in preclinical models.
Universal influenza vaccine candidate (dityrosine‑stabilized headless HA)
A trimeric HA stalk (headless HA) immunogen produced by first stabilizing the HA stalk with targeted crosslinks and then removing the head domain via engineered protease sites to focus immune responses on conserved stalk epitopes.
Epstein‑Barr virus vaccine candidate (dityrosine‑stabilized gB / gH‑gL and gp350)
Stabilized EBV envelope glycoprotein complex and gp350 immunogens engineered with targeted crosslinks to present functionally relevant conformations and elicit neutralizing antibody responses across EBV strains.
RSV vaccine candidate (dityrosine‑stabilized prefusion F)
A recombinant prefusion F protein immunogen stabilized by targeted dityrosine crosslinks to retain prefusion conformation, increase thermostability and elicit higher neutralizing antibody titers in preclinical models.
Universal influenza vaccine candidate (dityrosine‑stabilized headless HA)
A trimeric HA stalk (headless HA) immunogen produced by first stabilizing the HA stalk with targeted crosslinks and then removing the head domain via engineered protease sites to focus immune responses on conserved stalk epitopes.
Epstein‑Barr virus vaccine candidate (dityrosine‑stabilized gB / gH‑gL and gp350)
Stabilized EBV envelope glycoprotein complex and gp350 immunogens engineered with targeted crosslinks to present functionally relevant conformations and elicit neutralizing antibody responses across EBV strains.
Services
Collaborative platform licensing and research partnerships
Collaborative research, grant partnerships and potential licensing of platform approaches to apply targeted crosslink stabilization to vaccine programs.
Process development and technology transfer for vaccine manufacture
Development of upstream and downstream processes, scale‑up, purification and tech transfer support for recombinant subunit vaccine candidates.
Collaborative platform licensing and research partnerships
Collaborative research, grant partnerships and potential licensing of platform approaches to apply targeted crosslink stabilization to vaccine programs.
Process development and technology transfer for vaccine manufacture
Development of upstream and downstream processes, scale‑up, purification and tech transfer support for recombinant subunit vaccine candidates.
Expertise Areas
- Protein engineering for vaccine immunogens
- Recombinant subunit vaccine development
- Preclinical immunogenicity and animal model testing
- Bioprocess development and scale‑up for biologics
Key Technologies
- Dityrosine‑mediated covalent crosslinking
- Structure‑based protein design
- Recombinant protein expression (mammalian/CHO)
- Enzymatic catalysis for crosslinking